itd 1

ITD1 是一个选择性的TGFβ受体抑制剂(IC50:460 nM)。

(+)-ITD-1 是一种TGF-β抑制剂，特别抑制TGF-β2，其IC50值为0.46 μM。它不仅促进TGF-βII型受体（TGFBR2）的降解，还促进心肌细胞的分化。此外，(+)-ITD-1 在小鼠胚胎干细胞（mESCs）的早期分化过程中，有效抑制中胚层的形成。

FLT3-ITD/D835Y-IN-1 (Compound 1) 是一种FLT3-ITD和BCR-ABL的抑制化合物。该化合物通过抑制FLT3和BCR-ABL途径以及其他潜在靶点来诱导细胞促凋亡 (apoptosis)。FLT3-ITD/D835Y-IN-1 适用于急性髓性白血病 (AML) 研究。

FLT3/ITD-IN-1 (Compound 1) is a highly potent inhibitor of FLT3 internal tandem duplications (FLT3-ITD). It exhibits remarkable inhibitory effects against FLT3 and FLT3-ITD, with impressive IC50 values of 38.2 nM and 144.1 nM, respectively. Moreover, FLT3/ITD-IN-1 shows exceptional antiproliferative activities against several acute myeloid leukemia cell lines [1].

PDGFRα/FLT3-ITD-IN-1 是 PDGFRα/FLT3 的有效抑制剂，他们的 IC50 值分别大于 0.036 和 0.003 μM。 PDGFRα/FLT3-ITD-IN-1 对急性髓系白血病或慢性嗜酸性粒细胞白血病表现出研究潜力。

PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD) with an IC50 of 0.6 nM and exhibits anti-proliferative activity.

AC-4-130是一种直接的STAT5 SH2结构域抑制剂，能够破坏STAT5激活、二聚化、核易位和STAT5依赖性基因转录，在白血病细胞中诱导细胞周期停滞和细胞凋亡，可用于研究急性髓系白血病 (AML)。

Sorafenib N-oxide is an active metabolite of sorafenib , an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases. Sorafenib N-oxide inhibits FLT3 that contains the internal tandem duplication mutation (FLT3-ITD; Kd = 70 nM) and inhibits proliferation of MV4-11 acute myeloid leukemia (AML) cells expressing FLT3-ITD (IC50 = 25.8 nM). It is selective for AML cell lines containing FLT3-ITD over lines containing wild-type FLT3 (IC50s = 3.9-13.3 μM). Sorafenib N-oxide is also a linear-mixed inhibitor of the cytochrome P450 (CYP) isoform CYP3A4 (Ki = 15 μM in human liver microsomes).

Desmorpholinyl Quizartinib-PEG2-COOH is a compound featuring an FLT-3 ligand and a PEG-based PROTAC linker. It is employed in the synthesis of PROTAC FLT-3 degrader 1, which serves as a degrader for the FLT-3 internal tandem duplication (ITD) through PROTAC technology. The degrader exhibits an IC50 of 0.6 nM.

HDAC10-IN-2 (化合物 10c) 调节侵袭性 FLT3-ITD 阳性急性髓系白血病细胞的自噬。HDAC10-IN-2是HDAC10的高选择性抑制剂 (IC50 = 20 nM)。

HDAC10-IN-1 (化合物 13b) 是一种有效且高选择性的HDAC10抑制剂 (IC 50 = 58 nM)，可用于调节侵袭性 FLT3-ITD 阳性急性髓系白血病细胞的自噬。

HP1142 is a highly effective and specific inhibitor targeting the FLT3 receptor tyrosine kinase, with a particular affinity for its mutant variant FLT3/ITD. It exhibits a benzoimidazole scaffold-based structure, making it a promising compound for investigating and studying the FLT3/ITD mutation in the context of leukemia research [1].

HP1328 is a highly effective inhibitor of FLT3 receptor tyrosine kinase with a specific focus on FLT3/ITD mutation. It belongs to the benzoimidazole scaffold-based compound family. Significantly reducing the leukemia burden, HP1328 effectively extends the survival of mice afflicted with FLT3/ITD leukemia [1].

FLT3/TrKA-IN-1 是一种有效的 FLT3/TrKA 双激酶抑制剂，能够作用于 FLT3 (IC50: 43.8 nM)、FLT3-ITD (IC50: 97.2 nM)、FLT3-TKD (IC50: 92.5 nM) 和 TrKA (IC50: 23.6 nM)。FLT3/TrKA-IN-1 能够将细胞周期阻滞在 G0/G1 期，并诱导细胞凋亡 (apoptosis)，具有抗增殖作用。FLT3/TrKA-IN-1 具有潜力进行急性髓性白血病 (AML) 的研究。

FI-700 is a novel and potent FLT3 inhibitor with promising antileukemia activity. FI-700 showed a potent IC(50) value against FLT3 kinase at 20 nmol/L in an in vitro kinase assay. FI-700 showed selective growth inhibition against mutant FLT3-expressing leukemia cell lines and primary acute myeloid leukemia cells, whereas it did not affect the FLT3 ligand (FL)-driven growth of Wt-FLT3-expressing cells. Oral administration of FI-700 induced the regression of tumors in a s.c. tumor xenograft model and increased the survival of mice in an i.v. transplanted model. Furthermore, FI-700 treatment eradicated FLT3/ITD-expressing leukemia cells, both in the peripheral blood and in the bone marrow. (Source: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4575-82.)

BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy.

GTP-14564是一种新型酪氨酸激酶抑制剂，对 wt-FLT3和ITD-FLT3也具有抑制作用。GTP-14564 在 3μ m 处抑制表达 ITD-FLT3 的白细胞介素-3 非依赖性 Ba/F1 的生长，而需要高 30 倍的 GTP-14564 浓度来抑制表达野生型 FLT3 的 Ba/F3 的 FLT3 配体依赖性生长 （wt-FLT3）。

PF15是一种将FLT3 kinase配体与CRBN配体结合的PROTAC，它是FLT3-ITD的高选择性降解剂，显示出76.7 nM的DC50。该化合物能有效抑制FLT3-ITD阳性细胞增殖，并降低FLT3和STAT5的磷酸化水平。在小鼠模型中，PF15也能够抑制肿瘤生长，对白血病研究具有潜在应用价值。

PROTACFLT3/CDK9 degrader-1 是一种有效的FLT3和CDK9双PROTAC 降解剂。PROTACFLT3/CDK9 degrader-1 诱导细胞凋亡 (Apoptosis) 并有效降解靶蛋白FLT3和 CDK9。PROTACFLT3/CDK9 degrader-1具有研究 FLT3-ITD 突变型 AML 的潜力。

PF15 TFA是一种连接FLT3 kinase配体和CRBN配体的PROTAC，作为FLT3-ITD的高选择性降解剂，DC50值为76.7 nM。该化合物可显著抑制FLT3-ITD阳性细胞增殖，并降低FLT3和STAT5磷酸化水平。PF15 TFA亦能抑制小鼠模型的肿瘤生长，并可用于白血病研究。

HDAC10-IN-2 hydrochloride（化合物10c）是一种对HDAC10具有高效性和高选择性的抑制剂，IC50值为20 nM。该化合物能够调控FLT3-ITD阳性急性髓系白血病细胞的自噬过程。

Antiproliferative agent-30 (Compound 8g) 抑制微管蛋白组装且可抑制FLT3及Abl1。该化合物展现出对血管的破坏活性，并对多种癌细胞系表现出强效的抗增殖能力，包括HCT-116、K562及MV-4-11细胞（IC50值分别为0.054 nM、0.008 nM、0.144 nM）。此外，Antiproliferative agent-30 亦对携带FLT3-ITD-TKD突变的AML显示出抗癌效果。

FLT3-IN-21（复合物LC-3）是一种高效的FLT3抑制剂，具有促进细胞凋亡的能力，其对FLT3酶的半抑制浓度（IC50）为8.4 nM。该化合物能够使细胞周期在G1期停滞，并对FLT3-ITD阳性的AML细胞系MV-4-11显示出显著的抑制作用（IC50：5.3 nM）。在小鼠体内，FLT3-IN-21以每日10 mg/kg的剂量可以有效抑制MV-4-11细胞异种移植瘤的生长，肿瘤生长抑制率（TGI）达到92.16%。

FLT3-IN-20（compound 34f）作为一种高效FLT3抑制剂，对FLT3-D835Y和FLT3-ITD具有强效性，IC50值分别仅为1 nM和4 nM。该化合物在携带FLT3-ITD突变的AML细胞系MV4-11和MOLM-13中展现出显著的抗增殖效果，其中IC50值分别为7 nM和9 nM；对于带有FLT3-ITD-D835Y突变的MOLM-13变体，其IC50值为4 nM。FLT3-IN-20主要用于肿瘤治疗研究领域。